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Alterations in plasminogen activation correlate with
epithelial cell dysplasia grading in colorectal adenomas
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Summary Proteases are important for neoplastic invasion but a specific role for the plasminogen activator system in the progression of
colorectal epithelial dysplasia to adenomatous lesions remains unclear. Consecutive tissue cryosections of 51 adenomas, 49 distant mucosa
samples and five mucosa samples from control subjects were histopathologically analysed for dysplasia grade and tissue type, urokinase
plasminogen activator levels and plasminogen activator inhibitor type 1 (PAI-1) using immunosorbent methods. Plasminogen activation and
urokinase-mediated proteolytic activity levels were assessed using in situ zymography. Plasminogen activation and tissue-type activator levels
were lower in adenomas than in mucosae (P < 0.001). PAI-1 concentration and urokinase levels were higher in adenomas than in mucosae
(P < 0.001 and P < 0.001 respectively). In adenomas, urokinase concentration increased in parallel with PAI-1, but only the urokinase levels
correlated with the dysplasia grade (P< 0.01). Thus, the alterations in plasminogen activation correlated with epithelial cell dysplasia grading.
In the mucosa to adenoma transition, a marked decrease in tissue-type plasminogen activator occurred. In adenomas, this decrease was
accompanied by a concomitant increase in urokinase and PAI-1. The urokinase level only continued to rise in parallel with the dysplasia
grade. Resulting protease-antiprotease imbalance in high-grade dysplasia may represent the phenotypic change associated with malignant
transformation and invasive behaviour.
Keywords: colorectal adenoma; epithelial cell dysplasia; plasminogen activator inhibitor type 1; tissue-type plasminogen activator;
urokinase-type plasminogen activator
A series of phenotypic changes are associated with the malignant
conversion of the colorectal epithelium. The grade of epithelial
cell dysplasia is a hallmark of malignant potential in the process
known as the adenoma-carcinoma sequence (Muto et al, 1975;
O'Brien et al, 1990; Hamilton, 1992). While the morphological
changes taking place during the development and progression of
colorectal dysplasia can readily be detected by histopathology, the
proteolytic alterations underlying these multiple events remain
unclear.
It has been shown that components of the plasminogen activa-
tion system are key participants in the regulation of extracellular
matrix turnover during cell migration, tissue modelling and malig-
nant invasion (Konishi et al, 1982; Vassalli et al, 1991; Blasi,
1993). Previous studies have shown that tissue extracts from
colorectal carcinomas have increased levels of urokinase-type
plasminogen activator (uPA) and plasminogen activator inhibitors
(PAI) and decreased levels of tissue-type plasminogen activator
(tPA) compared with morphologically normal adjacent mucosa
(Gelister et al, 1986; Sier et al, 1991a). In adenomas, the levels of
activators and inhibitors appear to be between those found in
normal mucosa and those found in carcinoma (Gelister et al, 1986;
Bruin et al, 1987; Sim et al, 1988; Suzumiya et al, 1988; Sier et al,
1991a). A recent study reported that disturbances in the
plasminogen activator system in the colorectum are maximal in
invasive neoplasia (Delbaldo et al, 1995), but the data were only
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qualitative and a relationship to the epithelial dysplasia in
adenomas was not found. Studies examining a likely association
between uPA levels and the grade of dysplasia in colorectal
adenomas have reported contradictory results (de Bruin et al,
1988; Sim et al, 1988; Suzumiya et al, 1988; Sier et al, 1991b).
Moreover, the epithelial morphology may vary considerably
among regions of individual adenomas. A microheterogeneity
within adenomas might be a source ofvariations in previous works
aiming at correlating the biochemical findings in adenoma tissue
extracts with histological results in adjacent adenoma fragments
(de Bruin et al, 1988; Sim et al, 1988; Suzumiya et al, 1988).
In the present study, we have correlated the grade of epithelial
cell dysplasia with the extent ofplasminogen activation, as well as
the tPA, uPA and PAI-I levels, in a series of large colorectal
adenomas. To examine the relation between molecular changes
and morphology, we have adapted the technique of histozymog-
raphy to a semiquantitative assessment of plasmin generation in
tissue sections. In parallel, we have performed alternating histo-
logical and biochemical evaluations in serial tissue sections. Our
aim was to evaluate in situ the interplay between the histopatho-
logical changes found in the epithelium and the alterations in the
plasminogen activator/plasmin system.
MATERIALS AND METHODS
Patients and tissue samples
Fifty-one sporadic cases ofpedunculated colorectal adenomas from
19 women and 32 men (mean age 64.1 years) without a history
of hereditary non-polyposis colorectal cancer, familial colorectal
cancer or familial adenomatous polyposis were prospectively
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included in this study between January 1992 and October 1993.
Fourpatients hadundergone previous adenoma resection in the past
10 years. Two patients also had concurrent carcinoma of the colon
and nineteen patients had one or several concurrent adenomas. All
patients are currently undergoing an endoscopic and clinical
follow-up. This follow-up is performed 5 years from inclusion to
our study.
Adenomas were resected during elective colonoscopy and were
of at least 1 cm diameter and, in cases ofmultiple adenomas, only
the adenoma with the most advanced degree of dysplasia was
included in the study. Immediately after endoscopic removal, a
lateral part of the adenoma was frozen in liquid nitrogen-cooled
2-methylbutane and stored at - 80°C. The remaining part of the
adenoma was referred for routine histological examination.
Biopsies, of distant but apparently normal colorectal mucosa
(distant mucosa) were performed in all patients with adenoma.
Three biopsies per site were taken from the hepatic flexure, the
sigmoid and the rectum. All biopsies were made at least 20 cm
distant from the adenoma, and the three biopsies from each
location were taken within an area of 1 cm2. In addition, control
biopsies of normal colorectal mucosa (control mucosa) were
performed in the same manner on five control patients without
colorectal neoplasia or inflammatory bowel diseases; these
patients underwent colonoscopy for gastrointestinal bleeding
(three patients) or irritable bowel syndrome (two patients). All of
these patients had an endoscopically normal colorectal mucosa.
All biopsies were taken with the same type of forceps and with a
standardized technique to obtain approximately identical sampling
volumes. Two biopsies from each site were frozen and one was
referred for routine histological examination.
The study protocol was approved by the Ethics Committee of
the Faculty ofMedicine ofthe University ofLausanne. All patients
gave their written informed consent.
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Figure 1 Time of overlysis in mucosa from control subjects, in mucosa from
patients with adenomas and in adenomas with low- and high-grade dysplasia.
Results are presented as individual data points. Bars indicate medians; NS,
not significant; P, P-values calculated using Wilcoxon's rank sum test
Histopathological evaluations
On the lateral parts ofthe 51 adenomas, we made cryostat sections
for biochemical and histological experiments. Cryostat tissue
sections adjacent to those used for in situ zymography and
antigen/activity assays were stained with haematoxylin and eosin
(H&E) and examined by two experienced pathologists working in
parallel. Histological type and grade of dysplasia in the adenoma
were determined according to the criteria of the World Health
Organization (Jass and Sobin, 1989) and of the National Polyp
Study Group (Winawer et al, 1992). Low-grade dysplasia corre-
sponds to mild and moderate dysplasia and high-grade to severe
dysplasia. Adenomas were classified according to the highest
grade of dysplasia in the examined section. The biopsies from
normal and distant colorectal mucosa were referred for routine
histopathological examination to exclude inflammatory and
neoplastic lesions, e.g. aberrant crypts or microadenomas.
Because ofthe small amount oftissue, 2 ofthe 51 sets ofbiop-
sies from distant mucosa could not be studiedby histozymography
nor could the determinations for tPA, uPA and PAI-I antigen
concentrations and tPA activity be performed. For the same
reason, three adenomas could not be analysed for tPA, uPA and
PAI-I antigen concentrations and tPA activity.
Semiquantitative histozymography
Serial 7-gm cryostat sections of adenomas and biopsies of
colorectal mucosa from hepatic flexure ofpatients with adenomas
and controls were performed forthe in situ zymographic assays for
the total plasminogen activator activity (Sappino et al, 1991a and
b). Sections were overlaid with 100 jil of a suspension containing
2% non-fat dry milk, 0.9% agar and 40 jg ml-' ofpurified human
plasminogen (Chromogenix, Molndal, Sweden) in phosphate-
buffered saline (with 0.9 mm calcium chloride and 1 mm magne-
sium chloride). The overlay was covered with a glass cover slide
held on standard spacers. For the determination of in situ tPA and
uPA activity, the sameprotocol was performed applying an overlay
mixture containing 1 mm amiloride, a specific uPA inhibitor
(Vassalli et al, 1987), and polyclonal goat anti-human tPA
immunoglobulins G (0.2 mg ml-1) (Biopool, Ume'a, Sweden)
respectively. Overlay prepared in the absence ofplasminogen was
used as a control for non-specific caseinolytic activity. The over-
laid tissue sections were incubated in a humid chamber at 37°C.
The extent ofcaseinolysis, represented by a change to black ofthe
overlying suspension, was followed under the microscope with
dark-field illumination, and the progression of the caseinolysis
was photographically documented in intervals of 30 min. The
experimental end point was defined as complete caseinolysis
throughout the entire area ofthe tissue sections. The time between
the beginning and the end ofthe observation was called the time of
overlysis (TO). uPA activity was semiquantitatively assessed with
a score between 0 and 4 at 2 h from the beginning of the in situ
zymographic experiment (0, no activity; 1, traces of activity; 2,
low activity; 3, moderate activity; and 4, high activity).
Tissue extraction and protein concentration
Tissue extracts of adenomas were prepared from consecutive
250 jim-cryostat sections. Tissue extracts from colorectal mucosa,
distant and control, were obtained from pooled biopsies (one from
the hepatic flexure, two from the sigmoid and two from the
British Journal of Cancer (1998) 77(2), 297-304
NS
P<0.001
u~~~~~~~~~
.
P<0.001
_ mm ~~0
NS a"_
____
0 Gooses" s
m so 0 S *SSSSSS1S
u
0 CancerResearch Campaign 1998Plasminogen activation in colorectaladenomas 299
1A .1B
*. :;i: i- <:: fi 2, e . o:~~~ ~ ~~~~~...... .. :::: :: ;:: ....::.... i: ..
,ag.~~~ ~~~~~~~~ ~ ~~ ~ ~ ~ ~ ~~~ ~~~~~~~~~~~~~~~~~~ .......... _ ': .
.4 e .,y 8 x ....... ( ' . * L~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~......
...........,.........jC........
2A 2B
'"3 ..li
: @. '..}'''!^i'1~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~.....
_, .. ..^...:~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ ~~~~~~~~~~~ ~~~~~ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~......
3B~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~.0
WvKA~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
,^ ,', ffffF,'','5S,,, * ,i,.ffN'N',* an X,s,-'',,,'sE, %E :d ,<v:~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~......
' '1'' _^S,lEE<,,'t0kNg,SliESSlS!g00MFANdW$Ky~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~......
Figure 2 In situ zymographiesafter90 min of incubation in two consecutive sections of distant mucosa (1A and 1B), of an adenoma with low-grade dysplasia~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~.
.2 and 2B .n fa deoawt ih-rd.ypaia(Aad3).I.h..eis,tAatvt.i.lce ih nitAatboisad nth eis P
activityisblockedbyamiloride. Plasminogen-mediated caseinolysis appears as dark zones on the tissue sections. Plasminogen-mediated caseinolysisis tPA~~~~~~~~~~~~~~~~~~.
meitdi3 h uoaseien(A eaie 3Bxesv csioyi) dnmsso ot P-aduAmdae aenoyi 2 n B Aad3)
uPA-mediated~~ ~~~ actvit .....e peiper th.dnmascins(AadA,wil.P.ctvt.sditiueddfuel.vrth.ise.etos
......
British Journal ofCancer (1998) 77(2), 297-304 %,-W-ICancerResearch Campaign 1998300 P Protiva etal
tPAantigen concentration
NS
, 0 . . P<0.001
00
10
00 0
,0 e0
10
004
!0 NS 0 0~~~~~~~~~~~
0
0 oto itn Lo-grd Hihgrd
Control Distant Low-grade High-grade
mucosa mucosa dysplastic adenomas
I Controls I Patients
B
50-
40-
7
E 30-
-
2
aL 20-
10-
tPA activity
vNS
a P<0.001
i
S
: 0
%, NS
* +
Control Distant Low-grade High-grade
mucosa mucosa dysplastic adenomas
Figure 3 Concentration of tPA antigen levels (A) and tPA activity levels (B) in control subjects, in mucosa from patients with adenomas and in adenomas
with low- and high-grade dysplasia. Results are presented as individual data points. Bars indicate medians; NS, not significant; P, P-value of Wilcoxon's rank
sum test
rectum). The samples were homogenized by ultrasound sonication
in 200-300 g1 ofCamiolo buffer (0.075M potassium acetate, 0.3 M
natrium chloride, 0.1 M arginine, 0.01 M EDTA) with 0.25% Triton
X-100, pH 4.2, at4°C as described elsewhere (Markus et al, 1983).
The homogenates were centrifuged at 12 000 g for 10 min at 4°C.
The protein concentration in the supematant was assessed using
the dye-binding Bio-Rad protein assay (Bradford, 1976) (Bio-Rad,
Richmond, CA, USA).
Determination of PAI-i, uPA and tPA antigen levels and
tPA activity
The total amount of PAI-i antigen, i.e. latent, active and in
complex with activators, was determined by TintElize PAI-I
(Biopool, Ume'a, Sweden). To increase the PAI-1 detection limit to
0.3 ng ml-1, sample volumes of 40 g1 were used instead of the
recommended 20-gl volume (Sier et al, 1991a). The total amount
of uPA antigen was determined by TintElize uPA (Biopool). t-PA
antigen concentration was determined by TintElize tPA (Biopool).
The activity of tPA in tissue extracts was determined by
Chromolize tPA (Biopool).
Because the sample volumes from adenomas and biopsies were
very small, the amount oftissue available for the assays was corre-
spondingly low. Therefore, only tPA, uPA and PAI-I antigen levels
and tPA activity could be analysed.
Calculations and statistics
Antigen concentrations for uPA, tPA and PAI-I are expressed as
ng of antigen per mg of total protein. tPA activities are expressed
as intemational units per mg of total protein. Times of overlysis
(TO) are expressed in h. Results are given as mean ± s.e.m. In the
figures, medians or medians with quantiles are used for description
of both parametric and non-parametric data. Differences between
group means were tested for significance using the Wilcoxon's
rank sums test. Differences in scores were tested using the median
test. When both the factor and the response were nominal, the chi-
square test was performed. Correlations were tested using linear
regression analysis. Significance was defined as P < 0.05.
RESULTS
Size of resected adenomas and histological evaluation
Of the 51 adenomas, 12 were 1 cm, 23 were 1.1-2 cm and 16
adenomas were more than 2 cm in diameter, as measured before
fixation.
Histologically, there were 28 tubular, 19 tubulovillous and four
villous adenomas. Thirty-one adenomas were classified as being
low-grade and 20 as being high-grade dysplastic.
Nine of28 tubular adenomas as well as 8 out of 19 tubulovillous
adenomas showed high-grade dysplasia (P = 0.49 high-grade
dysplasia in tubular vs high-grade dysplasia in tubulovillous).
All four villous adenomas showed high-grade dysplasia. Villous
adenomas were more likely to be high-grade dysplastic than those
oftubular and tubulovillous architecture (P < 0.04).
No correlation was observed between the TO, the uPA, PAI-I
and tPA levels or the size and the histological type of adenomas,
categorized as tubular, villous or tubulovillous.
In addition to the histopathological evaluation of adenomas,
biopsy samples of distant colorectal mucosa from adenomas as
well as those from controls were analysed. None of these showed
any adenomatous or inflammatory changes.
Histozymography
Figure 1 shows the values of TO, as defined in the Materials and
methods section. TO was not different in five samples of control
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Figure 4 Concentration of uPA antigen measured by enzyme-linked
immunosorbent assay in control subjects, in mucosa from patients with
adenomas and in adenomas with low- and high-grade dysplasia. Results are
presented as individual data points. Bars indicate medians; NS, not
significant; P, P-values calculated using Wilcoxon's rank sum test
mucosa (1.50 ± 0.08 h, mean + s.e.m.) compared with 49 samples
ofdistant mucosa taken from the adenoma patients (1.51 ± 0.05 h,
P = 0.80). In contrast, the mean of the TO values in both control
and distant mucosae is markedly lower than that of 51 adenomas
(3.79 ± 0.22 h, P < 0.001), indicating that the level ofplasminogen
activation was diminished in adenomas compared with mucosae.
There was no significant difference in the TO between the 31
adenomas with low-grade dysplasia (3.45 ± 0.16 h) and the 20
adenomas with high-grade dysplasia (4.33 ± 0.46 h, P = 0.26).
Figure 2 illustrates the expression of in situ caseinolytic activi-
ties assessed in the presence of anti-tPA antibodies (Figure 2
1A-3A) or amiloride (Figure 2 1B-3B) in two consecutive
sections of the same sample of distant mucosa (Figure 2 1A and
IB), adenoma with low-grade dysplasia (Figure 2 2A and 2B) and
adenoma with high-grade dysplasia (Figure 2 3A and 3B). The
histozymograms of normal mucosae show that lysis was inhibited
by anti-tPA antibodies (Figure 2 lA) but not by amiloride (Figure
2 1B), indicating that it was tPA mediated. In adenomas, tPA-
mediated caseinolysis appeared to be associated with central
regions (Figure 2, 2B and 3B), whereas uPA-mediated lysis was
predominant in the periphery (Figure 2, 2A and 3A).
No uPA activity was detected in five sample sets of control
mucosa. uPA activity was present in 11 out of49 distant mucosae
sample sets (P = 0.12, chi-square test, controls vs distant). All
adenomas were positive for uPA activity (P < 0.001, chi-square
test, control mucosae vs adenomas; P < 0.001, distant mucosae vs
adenomas). tPA activity was present in all mucosa and adenoma
samples.
tPA antigen concentration
Figure 3A shows tPA antigen concentrations in five samples of
control mucosa and 49 samples of distant mucosae, and in 48
adenomas with low- and high-grade dysplasia. There was no
significant difference in tPA antigen concentrations between
control mucosae (58.95 ± 5.95 ng mg-' protein) and distant
mucosae (49.46 ± 2.39 ng mg-' protein, P = 0.19). Both control
and distant mucosae had higher tPA antigen concentrations than
adenomas (7.88 ± 0.47 ng mg-' protein, P < 0.001). Moreover, the
tPA antigen levels in normal and distant mucosae showed no
overlap with those in adenomas. The tPA antigen concentration in
29 adenomas with low-grade dysplasia (8.01 ± 0.60ng mg-'
protein) was not different from that in 19 adenomas with high-
grade dysplasia (7.69 ± 0.76 ng mg-1 protein, P = 0.95).
tPA activity
The tPA activity levels in control and distant mucosae and in
adenomas with low- and high-grade dysplasia are reported in
Figure 3B. The tPA activity levels in control mucosa (21.47
+ 3.20 IU mg-' protein) did not differ from those in distant mucosa
(19.44 ± 1.20 IU mg-1 protein, P = 0.53). Both the control and the
distant mucosae had extremely higher levels of tPA activity than
did adenomas (3.71 ± 0.20 IU mg-' protein, P < 0.001). There was
no significant difference in tPA activity levels between adenomas
with low-grade (3.92 ± 0.26 IU mg-' protein) and those with high-
grade (3.38 ± 0.28 IU mg-1 protein, P = 0.18) dysplasia.
In addition, there was a linear correlation between tPA antigen
and activity levels both in distant mucosa (r= 0.88, P < 0.001) and
in adenomas (r = 0.84, P < 0.001; data not shown).
PAI-i concentration
In 33 of49 samples ofdistant mucosa and in control mucosa, PAI-
1 levels were below the detection limit. In all these samples, PAI- I
antigen concentrations were considered as being equal to the
detection threshold. PAI-I concentrations in control mucosae
(0.11 ± 0.02 ng mg-1 protein) were not significantly different from
those in distant mucosae (0.17 ± 0.01 ng mg-1 protein, P = 0.08).
In contrast, in 48 adenomas, the levels of PAI-I were higher
(0.93 ± 0.14 ng mg-' protein) than those in control and distant
mucosae (P < 0.001). PAI-i antigen concentrations in adenomas
with high-grade dysplasia (1.20 ± 0.31 ng mg-1 protein) were
not different from those in adenomas with low-grade dysplasia
(0.76 ± 0.11 ng mg-' protein, P = 0.78).
In addition, PAI-i concentration was negatively correlated
with tPA concentration (r = - 0.36, P = 0.01) and tPA activity
(r = - 0.44, P < 0.002; data not shown).
uPA concentration
Figure 4 shows the uPA antigen concentrations in control and
distant mucosae as well as in adenomas with low- and high-grade
dysplasia. No significant difference in uPA antigen concentration
was found between five control mucosae (1.31 ± 0.13 ng mg-'
protein) and 49 distant mucosae (1.48 ± 0.14 ng mg-' protein, P =
0.86). The 48 adenomas had higher uPA antigen concentrations
(4.38 ± 0.31 ng mg-' protein) than control (P = 0.001) and distant
mucosae (P < 0.001). The adenomas with low-grade dysplasia had
lower uPA antigen concentrations (3.66 ± 0.31 ng mg-' protein)
than did adenomas with high-grade dysplasia (5.48 ± 0.56 ng mg-1
protein, P < 0.01), indicating that uPA protein concentration
correlates with the degree of dysplasia in colorectal adenomatous
epithelium.
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In addition, there was a positive linear correlation between uPA
and PAI-I antigen concentrations in adenomas (r = 0.73, P <0.001;
data not shown).
uPA activity
The uPA-mediated plasminogen-dependent caseinolysis was
scored on tissue sections by histozymography as defined in the
Material and methods. The adenomas had distinctly higher scores
for caseinolysis (2.30 ± 0.10) than did controls (0.00 ± 0.00) or
distant mucosae (0.29 ± 0.09, P < 0.001), indicating that uPA
activity is increased in adenomas. Moreover, the adenomas with
high-grade dysplasia showed higher scores for caseinolysis
(2.57 ± 0.19) than those with low-grade dysplasia (2.12 ± 0.09,
P < 0.03). There was no difference between the controls and
distant mucosae (P = 0.25).
uPA/PAI-1 ratio and the grade of dysplasia
The uPA/PAI-1 antigen ratios were calculated in 48 adenomas.
There was a trend for lower uPA/PAI-1 ratios in 29 adenomas with
low-grade dysplasia (6.83 ± 1.25) than in 19 adenomas with high-
grade dysplasia (11.55 ± 2.06, P = 0.09).
DISCUSSION
In the present study, we performed a combination of quantitative
antigen/activity determinations, semiquantitative histozymo-
graphic analyses and histopathological assessments in consecutive
cryostat tissue sections of adenomas and normal colorectal
mucosa. We have been able to correlate the alterations in the plas-
minogen activator/plasmin proteolytic system found in colorectal
adenomas with the grade of epithelial cell dysplasia. Using semi-
quantitative histozymography, we have shown that plasminogen
activator-mediated caseinolytic activity is diminished in adenomas
compared with mucosa samples. In normal mucosa, the major
source ofplasminogen-mediated caseinolysis is due to tPA, hence
the decreased level of plasminogen activation in adenomas can be
assigned to lowered tPA activity. These histozymographic data on
tPA are in agreement with the results of previous studies on tissue
homogenates (de Bruin et al, 1988; Suzumiya et al, 1988; Sier et
al, 1991a). Using antigen/activity immunosorbent methods
together with an efficient tissue extraction procedure (Camiolo et
al, 1982), we could demonstrate a clear-cut reduction in the tPA
levels in adenomas compared with control and distant mucosae.
The tPA antigen assay used in this study detects both free tPA and
tPA complexed with inhibitor (Ranby et al, 1989). Additionally,
we showed a linear correlation between the values of tPA antigen
and activity in both mucosae and adenomas. Thus, low tPA activity
in adenomas can mainly be attributed to a low protein level rather
than to an effect of inhibitors alone. This observation contradicts
the previous hypothesis claiming that diminution of tPA catalytic
activity is linked to the up-regulation of endothelial PAI-I in the
stromal compartment (Pyke et al, 1991a; Delbaldo et al, 1995).
tPA is mainly involved in intravascular fibrinolysis and in both
normal and neoplastic colorectum. tPA mRNA is readily detected
in the endothelium by in situ hybridization (Pyke et al, 1991a,
Delbaldo et al, 1995). Human neoplastic cells are known
to constitutively produce a variety of growth factors, cytokines
and positive chemotactic substances (Herlyn et al, 1991), and
some of these mediators, such as tumour necrosis factor a and
interleukin- 11, have been shown to down-regulate the tPA expres-
sion in human endothelial cells (Bevilacqua et al, 1986; Schleef et
al, 1988), suggesting that dysplastic colorectal epithelium may
down-regulate the tPA expression in the stroma by a paracrine
mechanism. Another explanation is that the minor effect of
inhibitors on tPA activity found in adenomas results from the direct
degradation of tPA/PAI-I complexes in tissue by monocytes, as
recently suggested using an in vitro model (Simon et al, 1995). The
lack ofsignificant differences in tPA levels between adenomas with
different grades of dysplasia suggests that a major decrease in tPA
levels occurs at an early stage of adenoma formation. In colorectal
cancer patients, low tPA levels in apparently normal colorectal
mucosa adjacent to tumour are associated with a poor overall
survival (Ganesh et al, 1994). This finding, together with our
observations, suggests that the role of tPA in the adenoma-carci-
noma sequence is perhaps more important than postulated in
previous studies. In our opinion, further studies examining the
mechanism of the down-regulation of tPA are needed to bring
insight onto the early stages ofcolorectal carcinogenesis.
Antigen levels of PAI-I were higher in adenomas and in distant
mucosa of subjects with an adenoma than in mucosa samples from
normal subjects. Similar to tPA, no correlation between the grade
of epithelial dysplasia and the level of PAI-I expression in
adenomas was found. This result is consistent with our previous
report that tissue distribution of PAI-I mRNA does not correlate
with the grade of dysplasia (Sordat et al, 1997). We thus assume
that PAI-1 up-regulation is an early event associated with adenoma
formation. Our data, and those of others, have demonstrated that
endothelial cells of colorectal adenomas as well as of carcinomas
can accumulate PAI-I mRNA (Pyke et al, 1991a; Delbaldo et al,
1995; Sordat et al, 1997). Experimentally, PAI-I is expressed by
migrating endothelial cells (Pepper et al, 1992). It has been shown
in vitro that stimulation of angiogenesis results in an increase in
plasminogen activator activity followed by a rise in PAI-I expres-
sion to limit the excessive plasmin generation (Flaumenhaft et al,
1992). Therefore, we attribute this up-regulation of PAI-I to
paracrine modulations in the adenomatous stroma associated with
neo-angiogenesis and extracellular matrix remodelling.
As this study was based on endoscopically removed tissue
samples, the material was not large enough toperform PAI-2 deter-
minations. However, other authors have demonstrated that PAI-2
levels increase in parallel with PAI-I levels (Sier et al, 199la).
Using histozymography and antigen determination, we have
shown that uPA antigen as well as uPA-mediated caseinolysis is
increased in adenomas compared with control and distant
mucosae, this agrees with results from previous studies on tissue
homogenates (de Bruin et al, 1988; Suzumiya et al, 1988; Sier et
al, 1991a). Interestingly, in about 20% ofpatients with adenomas,
uPA-mediated caseinolysis was found in sections of distant
mucosa but was not detected in any ofthe control mucosae. It has
been reported previously that mucosae adjacent to colorectal
cancer express uPA activity levels similar to those from healthy
subjects (Gibson et al, 1991). However, other studies have shown
that histologically normal colorectal mucosa from cancer patients
had ahigherproliferation activity than its counterpart from normal
subjects (Terpstra et al, 1987; Ponz de Leon et al, 1988).
Therefore, we hypothesize that the proteolytic profile in adenoma-
bearing mucosa is, at least in some instances, different from the
mucosa from control subjects without colorectal neoplasia.
We have demonstrated that both uPA antigen and uPA-mediated
caseinolysis were highest in the adenomas with high-grade
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dysplasia. This result is consistent with our recent report that
stromal expression ofuPA mRNA in adenomas correlates with the
grade of dysplasia in adjacent epithelium (Sordat et al, 1997). In
previous studies, acorrelation between uPA levels and the grade of
dysplasia could either not be established (de Bruin et al, 1988; Sim
et al, 1988) or it was suggested using a small series of adenomas
(Suzumiya et al, 1988). A combined determination of uPA levels
and dysplasia grade in consecutive cryostat sections allowed us to
demonstrate the significant correlation between biochemical
events and histopathological findings in adenomas. Several studies
showed that in both colorectal cancer and adenoma, the changes in
uPA levels originate in the stroma (Pyke et al, 1991b; Koretz et al,
1993; Delbaldo et al, 1995; Sordat et al, 1997). Thus, the parallel
increase in uPA and PAI-I antigen levels detected in adenomas
suggests that both components might be regulated, at least in part,
by the same paracrine stimuli. However, only the uPA levels
correlated with the grade of dysplasia, possibly shifting the
protease-antiprotease balance in favour of higher net proteolytic
activity in the areas of high-grade dysplasia. Indeed, there was a
trend for lower uPA/PAI-1 antigen ratios in low-grade dysplastic
adenomas compared with high-grade dysplastic adenomas. As
high uPA levels associate with metastatic potential in various types
of human cancers (Foekens et al, 1992; Schmitt et al, 1992;
Sumiyoshi et al, 1992; Grondahl-Hansen et al, 1993; Pujade-
Lauraine et al, 1993), we hypothesize that this protease-antipro-
tease imbalance found in high-grade dysplasia represents a marker
for the transition towards the invasive behaviour in adenomatous
lesions.
In conclusion, we have shown that the grade of epithelial
dysplasia in the colorectum correlates with defined alterations in
the plasminogen activator/plasmin system. These observations
support the hypothesis that high-grade dysplasia is a critical
marker ofmalignant transition in colorectal adenoma. The clinical
relevance ofthese findings will be established in ourfuture studies,
after completed follow-up ofall patients.
ABBREVIATIONS
PAI-1, plasminogen activator inhibitor type 1; PAI-2, plasminogen
activator inhibitor type 2; TO, time of overlysis; tPA, tissue-type
plasminogen activator; uPA, urokinase-type plasminogen activator
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